Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.
作者信息
Olutogun Tolulase, Cutini Ilaria, Notaro Rosario, Luzzatto Lucio
机构信息
Core Research Laboratory, Tumour Institute of Tuscany, Careggi Hospital, Florence, Italy.
Department of Haematology, University College Hospital, Ibadan, Nigeria.
出版信息
Blood Transfus. 2015 Jul;13(3):363-9. doi: 10.2450/2015.0249-14. Epub 2015 Feb 2.
Abstract
摘要
相似文献
1
Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.
Blood Transfus. 2015 Jul;13(3):363-9. doi: 10.2450/2015.0249-14. Epub 2015 Feb 2.
2
Paroxysmal nocturnal haemoglobinuria.
Clin Haematol. 1975 Feb;4(1):199-229.
3
RBC transfusions in paroxysmal nocturnal hemoglobinuria.
Arch Intern Med. 1977 Apr;137(4):536-8.
4
Effect of phenothiazine on the red cells of paroxysmal nocturnal haemoglobinuria.
Br J Haematol. 1968 Apr;14(4):345-50. doi: 10.1111/j.1365-2141.1968.tb06986.x.
5
Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.
Blood Adv. 2019 Nov 26;3(22):3575-3578. doi: 10.1182/bloodadvances.2019000897.
6
[Effect of horseshoe crab blood lectin on complement mediated hemolysis of paroxysmal nocturnal hemoglobinuria-like erythrocytes].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1984 Feb;6(1):62-4.
7
Comparative sensitivity of the erythrocytes in paroxysmal nocturnal haemoglobinuria to haemolysis by acidified normal serum and by high-titre cold antibody.
Br J Haematol. 1960 Oct;6:362-71. doi: 10.1111/j.1365-2141.1960.tb06254.x.
8
Lysis of red blood cells in some haemolytic anaemias--the lytic effect of agkistrodon piscivorus venom in vitro.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1977;104(3):428-35.
9
Regulation of the alternative pathway of complement by pH.
J Immunol. 1987 May 15;138(10):3392-5.
10
Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria.
Hematol Oncol Clin North Am. 2009 Apr;23(2):333-46. doi: 10.1016/j.hoc.2009.01.014.
引用本文的文献
1
FDA approval of crovalimab: a milestone in paroxysmal nocturnal hemoglobinuria treatment.
Ann Med Surg (Lond). 2025 Jan 9;87(1):27-29. doi: 10.1097/MS9.0000000000002848. eCollection 2025 Jan.
2
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria.
Blood. 2025 Jan 2;145(1):127-140. doi: 10.1182/blood.2024025176.
3
The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.
J Comp Eff Res. 2023 Oct;12(10):e230055. doi: 10.57264/cer-2023-0055. Epub 2023 Sep 1.
4
Whole blood transfusion and paroxysmal nocturnal haemoglobinuria meet again: Minor incompatibility, major trouble.
Vox Sang. 2022 Nov;117(11):1323-1326. doi: 10.1111/vox.13354. Epub 2022 Sep 14.
5
Childhood aplastic anaemia with paroxysmal nocturnal haemoglobinuria clones: A retrospective single-centre study in South Africa.
Afr J Lab Med. 2022 Jun 6;11(1):1537. doi: 10.4102/ajlm.v11i1.1537. eCollection 2022.
6
Case Report: Oral Cimetidine Administration Causes Drug-Induced Immune Hemolytic Anemia by Eliciting the Production of Cimetidine-Dependent Antibodies and Drug-Independent Non-specific Antibodies.
Front Med (Lausanne). 2021 Sep 24;8:723167. doi: 10.3389/fmed.2021.723167. eCollection 2021.
7
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population.
Adv Ther. 2021 Aug;38(8):4461-4479. doi: 10.1007/s12325-021-01825-4. Epub 2021 Jul 17.
8
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
J Hematol Oncol. 2017 Jun 19;10(1):126. doi: 10.1186/s13045-017-0496-x.
本文引用的文献
1
Transfusion complications in thalassemias.
Transfusion. 2014 Apr;54(4):957-9. doi: 10.1111/trf.12576.
2
Genetic variants in C5 and poor response to eculizumab.
N Engl J Med. 2014 Feb 13;370(7):632-9. doi: 10.1056/NEJMoa1311084.
3
Complement and its receptors: new insights into human disease.
Annu Rev Immunol. 2014;32:433-59. doi: 10.1146/annurev-immunol-032713-120154. Epub 2014 Jan 29.
4
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
Blood. 2014 Mar 27;123(13):2094-101. doi: 10.1182/blood-2013-11-536573. Epub 2014 Feb 4.
5
Targeted therapy with eculizumab for inherited CD59 deficiency.
N Engl J Med. 2014 Jan 2;370(1):90-2. doi: 10.1056/NEJMc1308104.
6
The complement system. Overview.
Methods Mol Biol. 2014;1100:1-9. doi: 10.1007/978-1-62703-724-2_1.
7
Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing.
Vox Sang. 2014 Apr;106(3):197-208. doi: 10.1111/vox.12086. Epub 2013 Oct 9.
8
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Haematologica. 2014 Feb;99(2):262-6. doi: 10.3324/haematol.2013.090001. Epub 2013 Sep 13.
9
PNH from mutations of another PIG gene.
Blood. 2013 Aug 15;122(7):1099-100. doi: 10.1182/blood-2013-06-508556.
10
Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
Int J Hematol. 2013 Oct;98(4):406-16. doi: 10.1007/s12185-013-1404-y. Epub 2013 Aug 11.
Zotero 插件